Marc Soler

miRFlow: Rapid screening tests for gynaecological cancers and beyond.

miRFlow is offering a new screening test to improve early diagnosis and recurrence monitoring of gynaecological cancers in a personalised manner. By analysing genomic biomarkers in a few drops of blood, our technology delivers accurate results within minutes using standard hospital laboratory equipment. This breakthrough has the potential to reduce unnecessary biopsies and enable earlier diagnosis of both asymptomatic women from high-risk groups and women presenting with typical symptoms. Beyond a first test targeting endometrial cancer, the ultimate aim of miRFlow is to make precision diagnostics in women’s health faster, more accessible, and more equitable, addressing a long-standing gender gap in cancer care.